Jeffrey M. Trent

Jeffrey M. Trent

Auto-generated profile, based on publicly available information

Jeffrey M. Trent

Translational Genomics Research Institute Phoenix Arizona USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2014 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PRPilar Ramos
Pilar Ramos
AKAnthony N Karnezis
Anthony N Karnezis
DCDavid W Craig
David W Craig
ASAleksandar Sekulic
Aleksandar Sekulic
MRMegan L Russell
Megan L Russell
JTJeffrey M Trent
Jeffrey M Trent

15 July 2005 in Cancer Research
Verified
Journal Article
Open access
JQJian-Zhong Qin
Jian-Zhong Qin
JZJeffrey Ziffra
Jeffrey Ziffra
LSLawrence Stennett
Lawrence Stennett
BBBarbara Bodner
Barbara Bodner
BBBrian K. Bonish
Brian K. Bonish
BNBrian J. Nickoloff
Brian J. Nickoloff
Patients with metastatic melanoma or multiple myeloma have a dismal prognosis because these aggressive malignancies resist conventional treatment. A promising new oncologic approach uses molecularly targeted therapeutics that overcomes apoptotic resistance and, at the same time, achieves tumor selectivity. The unexpected selectivity of proteasome inhibition for inducing apoptosis in cancer cells, but not in normal cells, prompted us to define the mechanism of action for this class of drugs, including Food and Drug Administration–approved bortezomib. In this report, five melanoma cell lines and a myeloma cell line are treated with three different proteasome inhibitors (MG-132, lactacystin, and bortezomib), and the mechanism underlying the apoptotic pathway is defined. Following exposure to proteasome inhibitors, effective killing of human melanoma and myeloma cells, but not of normal proliferating melanocytes, was shown to involve p53-independent induction of the BH3-only protein NOXA. Induction of NOXA at the protein level was preceded by enhanced transcription of NOXA mRNA. Engagement of mitochondrial-based apoptotic pathway involved release of cytochrome c, second mitochondria-derived activator of caspases, and apoptosis-inducing factor, accompanied by a proteolytic cascade with processing of caspases 9, 3, and 8 and poly(ADP)-ribose polymerase. Blocking NOXA induction using an antisense (but not control) oligonucleotide reduced the apoptotic response by 30% to 50%, indicating a NOXA-dependent component in the overall killing of melanoma cells. These results provide a novel mechanism for overcoming the apoptotic resistance of tumor cells, and validate agents triggering NOXA induction as potential selective cancer therapeutics for life-threatening malignancies such as melanoma and multiple myeloma.

3 April 2017 in Genome Research
Verified
Journal Article
Open access
PDF file
WLWinnie S. Liang
Winnie S. Liang
WHWilliam Hendricks
William Hendricks
JKJeffrey Kiefer
Jeffrey Kiefer
JSJessica Schmidt
Jessica Schmidt
SSShobana Sekar
Shobana Sekar
JTJeffrey Trent
Jeffrey Trent
Genomic analyses of cutaneous melanoma (CM) have yielded biological and therapeutic insights, but understanding of non-ultraviolet (UV)-derived CMs remains limited. Deeper analysis of acral lentiginous melanoma (ALM), a rare sun-shielded melanoma subtype associated with worse survival than CM, is needed to delineate non-UV oncogenic mechanisms. We thus performed comprehensive genomic and transcriptomic analysis of 34 ALM patients. Unlike CM, somatic alterations were dominated by structural variation and absence of UV-derived mutation signatures. Only 38% of patients demonstrated driver BRAF/NRAS/NF1 mutations. In contrast with CM, we observed PAK1 copy gains in 15% of patients, and somatic TERT translocations, copy gains, and missense and promoter mutations, or germline events, in 41% of patients. We further show that in vitro TERT inhibition has cytotoxic effects on primary ALM cells. These findings provide insight into the role of TERT in ALM tumorigenesis and reveal preliminary evidence that TERT inhibition represents a potential therapeutic strategy in ALM.

31 August 2008 in Nature Genetics
Verified
Journal Article
Open access
PDF file
JSJielin Sun
Jielin Sun
SZSiqun Lilly Zheng
Siqun Lilly Zheng
FWFredrik Wiklund
Fredrik Wiklund
SISarah D Isaacs
Sarah D Isaacs
LPLina D Purcell
Lina D Purcell
JXJianfeng Xu
Jianfeng Xu
William Isaacs and colleagues report evidence for a second prostate cancer risk locus in the HNF1B gene at 17q12, ∼26 kb from the previously reported risk locus in this region. The two loci are separated by a recombination hot spot and contribute independently to prostate cancer risk. We carried out a fine-mapping study in the HNF1B gene at 17q12 in two study populations and identified a second locus associated with prostate cancer risk, ∼26 kb centromeric to the first known locus (rs4430796); these loci are separated by a recombination hot spot. We confirmed the association with a SNP in the second locus (rs11649743) in five additional populations, with P = 1.7 × 10−9 for an allelic test of the seven studies combined. The association at each SNP remained significant after adjustment for the other SNP.

9 September 2021 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
LFLi Tai Fang
Li Tai Fang
BZBin Zhu
Bin Zhu
YZYongmei Zhao
Yongmei Zhao
WCWanqiu Chen
Wanqiu Chen
ZYZhaowei Yang
Zhaowei Yang
WXWenming Xiao
Wenming Xiao

28 June 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HEHedyeh Ebrahimi
Hedyeh Ebrahimi
NDNazli Dizman
Nazli Dizman
LMLuis Meza
Luis Meza
JMJasnoor Malhotra
Jasnoor Malhotra
XLXiaochen Li
Xiaochen Li
SPSumanta K Pal
Sumanta K Pal
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab. However, its effect on those receiving tyrosine kinase inhibitor-based combinations is unknown. In this open-label, randomized, investigator-initiated, phase 1 study, 30 participants with locally advanced or mRCC with histological confirmation of clear cell, papillary or sarcomatoid component were randomized in a 2:1 fashion to receive cabozantinib (an inhibitor of vascular endothelial growth factor receptor, MET and AXL) and nivolumab (anti-programmed cell death protein 1) with or without CBM588 as first-line treatment. Metagenomic sequencing was performed on stool samples to characterize their gut microbiome at baseline and 13 weeks into treatment. The primary endpoint was a change in the relative abundance of Bifidobacterium spp.; secondary endpoints included objective response rate (ORR), progression-free survival (PFS) and toxicity profile. The primary endpoint of the study was not met and the addition of CBM588 to cabozantinib and nivolumab did not result in a difference in the relative abundance of Bifidobacterium spp. or alpha diversity (as measured by the Shannon index). However, ORR was significantly higher in participants treated with CBM588 compared to those in the control arm (14 of 19, 74% versus 2 of 10, 20%; P = 0.01). PFS at 6 months was 84% (16 of 19) and 60% (6 of 10) in the experimental and control arms, respectively. No significant difference in toxicity profile was seen between the study arms. Our results provide a preliminary signal of improved clinical activity with CBM588 in treatment-naive participants with mRCC receiving cabozantinib and nivolumab. Further investigation is needed to confirm these findings and better characterize the underlying mechanism driving this effect.ClinicalTrials.gov identifier: NCT05122546